Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy

Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy

Background: The 2018 American Society of Clinical Oncology/College of American Pathologists guidelines classified immunohistochemistry (IHC) 1+ or 2+, FISH-negative breast cancer as HER2-low. To date, only a few studies have investigated the role of HER2-low status in patients with hormone receptor...

Full description

Saved in:
Bibliographic Details
Main Authors: Federico Sottotetti, Barbara Tagliaferri, Gianpiero Rizzo, Raffaella Palumbo, Giulia Chessa, Chiara Raso, Lorenzo Perrone, Alberto Malovini, Valentina Tibollo, Laura Deborah Locati, Paolo Pedrazzoli, Angioletta Lasagna
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2025-05-01
Series:Drugs in Context
Subjects:
abemaciclib
antibody–drug conjugates
her2-low
metastatic breast cancer
palbociclib
ribociclib
therapeutic strategies
Online Access:https://www.drugsincontext.com/patterns-of-treatment-and-outcomes-of-patients-with-metastatic-her2-low-breast-cancer-treated-with-cdk4-6-inhibitors-and-hormone-therapy/
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.drugsincontext.com/patterns-of-treatment-and-outcomes-of-patients-with-metastatic-her2-low-breast-cancer-treated-with-cdk4-6-inhibitors-and-hormone-therapy/

Similar Items